JB Pharma records 12 per cent revenue growth in Q1, ET HealthWorld

Mumbai: JB Chemicals & Pharmaceuticals Ltd announced its financial results for the quarter ended June 30, 2024.

The company has recorded revenue of Rs 1004 crore in first quarter of FY25 registering growth of 12 per cent from Rs 896 crore in Q1 FY24. Operating earnings before interest depreciation and taxes (EBITDA) improved by 20 per cent to Rs 292 crore in Q1 FY25 as compared to Rs 243 crore in Q1 FY24. Profit after taxes registered strong growth of 25 per cent to Rs 177 crore in Q1 FY25 vs Rs 142 crores in Q1 FY24.

Nikhil Chopra, CEO and Wholetime Director, JB Pharma mentioned, “Our overall performance in the first quarter has been robust. We have reached a new milestone of Rs 1,000 crores in quarterly sales for the first time during any quarter, with improvement across all parameters — revenue, gross profit, operating profit and operating profit margin.

Strong performance in the domestic business has continued, with each of the big brand franchises witnessing market-beating growth. We expect the international business including CDMO business to pick-up in the second half of the financial year.

The good start in the first quarter augurs well for the balance fiscal year. We are confident about meeting our operating and strategic goals for the year and remain focused on making the organisation progressive and future ready.”